This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $480,990 to the University of Illinois to investigate the role of aerocytes, a recently identified capillary endothelial cell population, in regulating alveolar epithelial regeneration following lung injury. The research aims to establish the central role of aerocytes and the signaling molecule R-spondin3 in guiding the...
This $704,795 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Baylor College of Medicine supports the development of a novel cell-based immunomodulation therapy to suppress lung inflammation and promote repair in Acute Respiratory Distress Syndrome (ARDS). The project aims to engineer retinal pigment epithelial (RPE) cells to produce anti-inflammatory cytokines IL-1RA and IL-10 and encapsulate them in alginate-based...
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop clinically relevant approaches to correct endothelial cell (EC) dysfunctions, prevent loss of microvasculature, and slow the progression of lung fibrosis. The $695,403 award to the University of Arizona will test two specific aims: (1) determining whether restoring microvascular integrity via nanoparticle gene therapy can...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $322,480 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for research to define the role of endothelial sphingosine-1-phosphate receptor 1 (S1PR1) signaling in promoting lung repair and preventing pulmonary fibrosis after viral respiratory...
This Project Grant award of $775,992.00 from the National Heart, Lung, and Blood Institute (NHLBI)'s Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in the resolution of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The key objectives are to determine the function of Treg glucocorticoid receptor (GR) signaling and the impact of exogenous glucocorticoid...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $773,446 to The Washington University to conduct research on the spatiotemporal control of early matricellular events in the injured lung. The overarching goal is to better understand the mechanisms that stabilize the provisional matrix after lung injury, in order to identify potential therapeutic targets for acute lung injury/acute respiratory distress syndrome...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $602,955 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to National Jewish Health in Denver, Colorado. The 5-year grant, running from July 2024 to June 2029, will fund research to identify the unique functions and molecular drivers of airspace macrophage subsets during the resolution of lung inflammation and active lung repair. The primary objectives are to: 1) Test the hypothesis that a subset of airspace...
This Project Grant award of $1,220,472.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to study the use of adoptively transferred naive B cells to provide multi-organ protection in a mouse model of acute respiratory distress syndrome (ARDS) induced by hyperoxia. The key goals are to: Investigate the efficiency of B cell homing to the lungs and brain and characterize the phenotypes of B cells that traffic to these inflamed sites. Identify...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $200,502 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the molecular phenotypes and trajectories of acute respiratory distress syndrome (ARDS). The key objectives are to: Identify metabolite and protein drivers of ARDS evolution in patients with hyper-inflammatory and hypo-inflammatory ARDS...
This $186,408 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to evaluate CD14 as a potential therapeutic target for acute respiratory distress syndrome (ARDS). The project aims to: 1) determine the effects of the CD14-blocking antibody IC14 on cellular targets through blood leukocyte RNA sequencing analysis, 2) examine the relationship between the CD14-pathway biomarker presepsin...